Viracoat Ltd Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Location

Lancaster UK

Primary Industry

Biotechnology

About

Based in Lancaster, UK, Viracoat Ltd., a subsidiary of ViraCorp, operates as a biotechnology research company that developed and released a novel antiviral and antimicrobial coating material (ACM). As of 2022, Jon Chadwick is the CEO of the company. In September 2021, Viracoat raised GBP 2 million in venture funding from investors. The company offers a Virucidal FFP2 Mask with Neutrapodal™ technology to inactivate the virus and assist in limiting the spread of COVID-19 and other microorganisms. The firm's FFP2 mask has antiviral properties against SARS-CoV-2 (including new strains), influenza (PR8 strain), and bacteria (E. coli). ViraCoat's masks have five layers: the innermost layer, which touches the face, is made of a soft, absorbent non-woven fabric, followed by two layers of melt-blown cloth that together serve as a filter, and the outermost layer, which is hydrophobic Neutrapodal™-coated.

Current Investors

J.J. Richards & Sons Pty Ltd

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biotechnology

Website

www.viracoat.global

Verticals

Manufacturing

Company Stage

Early Stage

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.